BVI Secures CE Mark for Integrated Cataract and Vitreoretinal System

CE Mark in hand, BVI’s Virtuoso is ready to take on Europe. 

BVI Medical (USA) has secured CE Mark approval under the European Union Medical Device Regulation (EU MDR) for Virtuoso, its dual-function phaco-vitrectomy platform, clearing the way for commercialization across CE-recognized markets. The approval positions the Massachusetts-based company within the premium segment of ophthalmic surgical systems and signals a broader industry push toward integrated platforms that handle both anterior and posterior segment procedures within a single workflow. 

One platform, two segments 

Virtuoso is engineered to support cataract and vitreoretinal procedures on a single system, targeting multi-specialty centers and ambulatory surgical environments where case mix and turnover pressures are only intensifying. By integrating phacoemulsification and vitrectomy capabilities, the platform aims to reduce equipment redundancy in the OR.

“Virtuoso represents a significant advance in surgical equipment design, bringing together precision, intuitive ease of use that supports OR efficiency and world-class versatility for both the front and the back of the eye,” said BVI President and CEO Jim Hollingshead in a news release.

He added, “With CE Mark certification under the European Medical Device Regulation, we are making this leading-edge platform available to surgeons across Europe, designed to elevate surgical control, efficiency and outcomes, reflecting BVI’s continued commitment to meaningful innovation in eye health.”

For surgical teams, the consolidation approach carries practical implications around set-up time, equipment redundancy and intraoperative transitions, particularly in practices managing cataract and retinal disease within the same surgical session.

READ MORE: Intalight’s DREAM OCT Platform Cleared for EU Market with CE Mark

Early clinical signals 

Initial clinical evaluation is underway at the LMU Klinikum in Munich, where the first patient procedure was completed in December 2025. Early findings from this pre-market investigation point to stable fluidics behavior and responsive system performance during combined procedures, though broader validation remains ongoing. 

Prof. Dr. Siegfried Priglinger, chair of the Department of Ophthalmology at LMU Klinikum noted, “During this first phase of our clinical evaluation, Virtuoso has demonstrated a thoughtful integration of fluidics stability, responsiveness and workflow efficiency, designed with the realities of combined cataract and vitreoretinal surgery in mind, and we look forward to further evaluating its performance as the study progresses.”

Supporting data presented at major congresses—including EURETINA and ESCRS—have focused on system responsiveness, energy delivery consistency and aspiration efficiency relative to existing platforms. These early indicators provide a technical foundation, but longer-term outcomes and real-world reproducibility will ultimately determine clinical adoption. 

Positioning in a crowded premium segment

With CE Mark in hand, Virtuoso enters a competitive landscape where differentiation increasingly turns to workflow integration, versatility and efficiency rather than standalone performance metrics. BVI’s strategy appears to center on flexibility, offering a single platform capable of addressing diverse procedural needs while reducing the OR equipment footprint. 

The European rollout, expected in Q3 2026, will be the real test: can this approach gain traction in settings where surgeons remain accustomed to dedicated systems for anterior and posterior procedures?

READ MORE: Smart Tech in Refractive Surgery

The takeaway

BVI’s Virtuoso reflects a broader shift toward integrated cataract-retina platforms, where the conversation is moving from capability to execution. As dual-function design becomes table stakes, differentiation may hinge less on features and more on consistency—particularly fluidics stability and intraoperative control across procedural transitions.

Virtuoso plants its flag on both counts. Whether that promise holds up under real-world conditions will determine whether it earns a permanent place in an increasingly crowded OR.

Editor’s Note: This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.